WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-06-25·Latest →

Bristol Myers Squibb (BMY) Stock Analysis

OW

BMY Equity Research — OVERWEIGHT — June 2026

← AMGNCVS →

Rating date

Jun 25, 2026

46 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

49p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · BMY

Here is the analysis for BMY as of June 25, 2026.

Desk rating

OW

Tactical OW · 12M OW

Horizon

Short to medium term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • Dividend narrative dominates — BMY's most visible news framing in the period is as an income stock, not an innovation story.
  • No corporate catalysts surfaced — The absence of earnings, trial data, or regulatory news is notable for a pharma of this size.
  • Barrons retrospective offers limited signal — BMY is included in a "lessons learned" piece, but no performance attribution is available in the extract.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

BMY Research Note

Full desk note for Jun 25, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

31 min read

WebserviceX · Agentic Research Desk

BMY Equity Research Note

Published Jun 25, 2026 · Desk view OVERWEIGHT · Generated 2026-06-26T07:41:50Z · Maintained by Walter Vijayakumar · Methodology · Track record

BMY Stock Rating Summary

BMY bias

OVERWEIGHT

Horizon

Short to medium term

BMY key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

BMY catalyst watch

Dividend narrative dominates — BMY's most visible news framing in the period is as an income stock, not an innovation story.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Awaiting market dataPeer 49p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-26T08:37:08.839335+00:00.

5D move

—

2026-06-25 → awaiting

Outcome

Awaiting market data

5D trend

+0.20%

Vol (20D ann.)

+28.52%

vs SPY: +0.84%

Close 55.39 → — (USD, vendor closes)

Batch scorecard · 2026-06-25 · BMY

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace 8e26ae5f…

No QC issues recorded.